Iovance builds gene therapy manufacturing facility in Philadelphia

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/Sean Pavone)
(Image: Getty/Sean Pavone)

Related tags: Gene therapy, Gene therapy candidate, Manufacturing, facility, Production line

Iovance amps up clinical and commercial immunotherapy production with a $75m (€67.3m), 136,000 square-foot build in Philadelphia’s Navy Yard.
PARK_Iovance
Architectural rendering of new facility (Image: DAGSAU)

The late-stage biotech will increase its production capacity for its tumor-infiltrating lymphocyte (TIL) technology-based therapeutics with the Philadelphia site. Iovance, headquartered in the San Francisco Bay Area, has research facilities in Florida and New York, but this will be its first manufacturing facility.

Iovance’s new facility will enable the company to produce its TIL products and its lead drug candidate lifileucel – which is in Phase II studies for the treatment of advanced melanoma – through scalable processes.

TIL therapyuses treats a patient with their own immune cells and involves the collection of a patient’s tissue sample that is then shipped to a manufacturing facility for processing. For Iovance, this supply chain requires the cells to be cryopressed after processing and shipped back to the patient for infusion.

A spokesperson for Iovance told us that the company chose to build in the city’s centrally-located  Navy Yard as it is close to the airport and has efficient access to transportation, which he said are key factors for a cell therapy where a rapid turnaround is imperative for accessibility.

Maria Fardis, president and CEO of Iovance said in a statement, “Building our own internal production capabilities will help us reduce the cost of operations which is necessary for offering broad access to TIL therapy.”

According to the company, the site will be designed to manufacture enough products for thousands of patients annually in both a clinical and commercial capacity.  

The facility is expected to be complete in 2021.

Related news

Show more

Related products

show more

rAAV Production in BioBLU® Single-Use Vessels

rAAV Production in BioBLU® Single-Use Vessels

Eppendorf for Bioprocess – Solutions that grow with you | 25-Jun-2019 | Application Note

Rising interest in gene therapy-based applications leads to increasing demands in scalable production systems for viral vectors. Find out how Cevec Pharmaceuticals...

Small-Scale Cell Culture Perfusion Process

Small-Scale Cell Culture Perfusion Process

Eppendorf for Bioprocess – Solutions that grow with you | 29-Mar-2019 | Application Note

Perfusion cell culture processes promise advantages for industrial bioprocessing, like saving space, increasing volumetric productivity, achieving more...

Removing Aggregates of an Acidic Monoclonal Antibody

Removing Aggregates of an Acidic Monoclonal Antibody

Bio-Rad Laboratories | 22-Oct-2018 | Technical / White Paper

CHT Ceramic Hydroxyapatite Media/Resins are known as the industry gold standard for
impurity removal during monoclonal antibody (mAb) purification....

Single-Step Influenza and Dengue Virus Purification

Single-Step Influenza and Dengue Virus Purification

Bio-Rad Laboratories | 08-Oct-2018 | Application Note

CHT XT is the newest addition to the CHT family of media. It has been designed for superior physical robustness to ensure it can be used repeatedly over...

Related suppliers

Follow us

Products

View more

Webinars